Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0YHPUE
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
RC-108
|
|||||
| Synonyms |
RC108; RC 108
Click to Show/Hide
|
|||||
| Organization |
RemeGen Co., Ltd.
|
|||||
| Drug Status |
Phase 2
|
|||||
| Indication |
In total 3 Indication(s)
EGFR(+) non-small cell lung cancer [ICD11:2C25]
Phase 2
Gastroesophageal cancer [ICD11:2B71]
Phase 2
MET(+) solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Hepatocyte growth factor receptor (MET)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
Vedotin
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.